ondansetron has been researched along with Cardiovascular Stroke in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boshen, Y | 1 |
| Yuankang, Z | 1 |
| Taixi, L | 1 |
| Kaifan, N | 1 |
| Zhixiang, W | 1 |
| Liang, L | 1 |
| Chengxing, S | 1 |
| Xia, L | 1 |
| Xian, J | 1 |
2 other studies available for ondansetron and Cardiovascular Stroke
| Article | Year |
|---|---|
Effects of ondansetron treatment on outcomes of critically ill patients with myocardial infarction partly through its anti-inflammatory activity.
Topics: Critical Care; Critical Illness; Humans; Intensive Care Units; Myocardial Infarction; Ondansetron; R | 2023 |
Reports from the University Hospital Consortium (UHC) Technology Advancement Center.
Topics: Academic Medical Centers; Drug-Related Side Effects and Adverse Reactions; Multicenter Studies as To | 1995 |